In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
about
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsTherapeutic decisions in multiple sclerosis: moving beyond efficacyEfficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats.Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.Dimethyl fumarate : a Janus-faced substance?The fumaric acid ester BG-12: a new option in MS therapy.Tecfidera(®): an approach for repurposing.Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions.Fumaric acid esters in dermatology.Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.Fumaric acid esters in the management of psoriasis.Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.Dimethyl fumarate - only an anti-psoriatic medication?
P2860
Q26752859-BC7058E5-2465-4B80-BA8F-B5FE1FC0BF55Q28541039-E7A4ED3D-BFFE-4642-94F6-81F477D58B04Q34046298-7C52A446-D728-4578-A118-0034C290B37FQ35204440-E3EBB298-EF00-4199-839E-D00BEBD2B181Q36389688-3E9D6316-CF99-411E-932F-05BEBD48DEBBQ37720346-DA3E1FC0-D098-4603-88F4-1D8FB4D91588Q38108633-892426A8-9FD1-4943-B595-10B1C640856AQ38128863-F2323C84-C412-4E2F-8D27-A07C483EAC85Q38192708-67D016F3-165C-4E2A-B6DC-E9A3C095DD32Q39458847-46353311-4725-49E0-B301-04D7BF0F094EQ42401921-4059D720-2036-4624-8E0B-57A5E9FC01C2Q47318089-1B442784-11C8-4982-94B1-FB05A9B143F5Q48357779-A9A3EEF6-9CB5-4FC6-8B58-4A5049B4AADAQ54958047-15B7D9BC-EA87-4081-B27D-332EDB41AF50Q55117400-6F4981A0-EA4C-48A1-AF47-1916BE1B9425Q56639506-5C0D6263-CA01-4340-834D-C677B79BFD26
P2860
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@ast
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@en
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@nl
type
label
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@ast
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@en
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@nl
prefLabel
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@ast
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@en
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@nl
P2093
P2860
P356
P1433
P1476
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
@en
P2093
Co van Gulpen
Elisabeth van Strijen
H Bing Thio
Herman Mattie
Jaap T van Dissel
Peter H Nibbering
P2860
P2888
P356
10.1186/1471-2210-4-22
P407
P577
2004-10-12T00:00:00Z
P5875
P6179
1025546941